InnoPharmax Inc. (TPEX:4172)
Taiwan · Delayed Price · Currency is TWD 16.10
-0.10 (-0.62%)
Jan 22, 2026, 2:02 PM CST
InnoPharmax Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 55.77 | 32.3 | 46.07 | 29.13 | 48.06 | 136.88 | Upgrade | |
Revenue Growth (YoY) | 61.25% | -29.90% | 58.15% | -39.38% | -64.89% | 61.24% | Upgrade |
Cost of Revenue | 38.33 | 11.53 | 28.62 | 29.51 | 40.65 | 78.73 | Upgrade |
Gross Profit | 17.45 | 20.76 | 17.46 | -0.38 | 7.41 | 58.15 | Upgrade |
Selling, General & Admin | 24.18 | 21.43 | 22.97 | 21.51 | 22.43 | 24.17 | Upgrade |
Research & Development | 91.04 | 89.22 | 59.33 | 71.94 | 60.2 | 62.41 | Upgrade |
Operating Expenses | 116.56 | 116.74 | 82.3 | 92.95 | 81.79 | 88.47 | Upgrade |
Operating Income | -99.12 | -95.98 | -64.84 | -93.33 | -74.37 | -30.32 | Upgrade |
Interest Expense | -0.38 | -0.31 | -0.37 | -0.26 | -0.4 | -0.62 | Upgrade |
Interest & Investment Income | 2.9 | 1.92 | 1.64 | 0.98 | 1.01 | 0.79 | Upgrade |
Earnings From Equity Investments | -9.74 | -8.12 | -9.3 | -5.82 | -15.32 | -10.27 | Upgrade |
Currency Exchange Gain (Loss) | -1.66 | 0.4 | -0.07 | -0.13 | -0.79 | -0.89 | Upgrade |
Other Non Operating Income (Expenses) | 3.37 | 5.12 | 3.5 | -4.6 | 0.06 | 1.07 | Upgrade |
EBT Excluding Unusual Items | -104.63 | -96.97 | -69.43 | -103.15 | -89.81 | -40.24 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | -0.03 | - | - | Upgrade |
Asset Writedown | - | - | -1.4 | - | -3.16 | -3.66 | Upgrade |
Pretax Income | -104.63 | -96.97 | -70.83 | -103.18 | -92.97 | -43.9 | Upgrade |
Income Tax Expense | 2.32 | 2.32 | - | - | - | - | Upgrade |
Net Income | -106.95 | -99.29 | -70.83 | -103.18 | -92.97 | -43.9 | Upgrade |
Net Income to Common | -106.95 | -99.29 | -70.83 | -103.18 | -92.97 | -43.9 | Upgrade |
Shares Outstanding (Basic) | 104 | 97 | 92 | 87 | 86 | 77 | Upgrade |
Shares Outstanding (Diluted) | 104 | 97 | 92 | 87 | 86 | 77 | Upgrade |
Shares Change (YoY) | 9.16% | 5.83% | 6.20% | 0.31% | 12.92% | 7.58% | Upgrade |
EPS (Basic) | -1.03 | -1.02 | -0.77 | -1.19 | -1.08 | -0.57 | Upgrade |
EPS (Diluted) | -1.03 | -1.02 | -0.77 | -1.19 | -1.08 | -0.57 | Upgrade |
Free Cash Flow | -99.95 | -76.75 | -48.97 | -100.08 | -51.48 | -47.37 | Upgrade |
Free Cash Flow Per Share | -0.96 | -0.79 | -0.53 | -1.15 | -0.60 | -0.62 | Upgrade |
Gross Margin | 31.28% | 64.29% | 37.89% | -1.29% | 15.43% | 42.48% | Upgrade |
Operating Margin | -177.71% | -297.18% | -140.73% | -320.35% | -154.76% | -22.15% | Upgrade |
Profit Margin | -191.76% | -307.43% | -153.74% | -354.17% | -193.44% | -32.07% | Upgrade |
Free Cash Flow Margin | -179.20% | -237.64% | -106.29% | -343.51% | -107.11% | -34.61% | Upgrade |
EBITDA | -97.22 | -93.92 | -62.12 | -89.41 | -69.33 | -20.52 | Upgrade |
EBITDA Margin | -174.31% | -290.81% | -134.83% | - | -144.25% | -14.99% | Upgrade |
D&A For EBITDA | 1.9 | 2.06 | 2.72 | 3.92 | 5.05 | 9.81 | Upgrade |
EBIT | -99.12 | -95.98 | -64.84 | -93.33 | -74.37 | -30.32 | Upgrade |
EBIT Margin | -177.71% | -297.18% | -140.73% | - | -154.76% | -22.15% | Upgrade |
Advertising Expenses | - | 0.33 | - | - | - | 0.12 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.